Clinical Trials Logo

Clinical Trial Summary

This study will help the investigator understand the pathogenesis of different rare genetic conditions and to establish database of rare genetic databases. This would ultimately help to provide more accurate diagnosis through advanced genomic diagnostic testing and databases established from this study. This knowledge would in turn help in the clinical management of other affected family members and other individuals affected with similar conditions. Understanding of pathogenesis of the disease would also enable the investigator to develop targeted therapies for rare genetic diseases, and also to collaborate on the targeted therapy-related clinical trials.

The investigator plans to store the results of this study in databases. These results will be shared with other researchers or doctors, who research, diagnose or treat the individuals with similar diseases.

The investigator will only share the data that is collected and not the biological samples.


Clinical Trial Description

This proposed study is designed identify for the genetic causes of rare diseases. This study does not involve the use of investigational medication or devices. No randomization will take place. Participants enrolled into the study will be asked to provide blood or saliva samples for DNA testing. Samples will be collected by one of two methods;

- If the participant has had a clinical genetic test performed, the results/data will be collected from the University of Kentucky (UK) clinical molecular pathology laboratory or from the medical records. If the cause of the disease is not identified on clinical genetic testing, the investigator will reanalyze the clinical genetic testing data or use the blood or saliva sample leftover from the clinical genetic testing for additional experiments using new methods to identify the cause of the disease.

- If no sample leftover from the clinical genetic testing is available, the investigator plans to collect about 2 teaspoons of blood or saliva from the participant at their first visit to the site.

This study plans to enroll 1000 participants from the University of Kentucky Medical Center.

The investigator plans to store any blood or saliva DNA samples collected for future research studies involving rare genetic diseases. The stored blood or saliva DNA samples will not be released to anyone outside the study.

Stored samples will be labeled with a unique study identifier and will be maintained in the investigator's research laboratory located at the University of Kentucky, Department of Pathology and Laboratory Medicine, 800 Rose Street, Lexington, KY 40536.

There is no limit on the length of time that the samples will be stored. The investigator may keep using the stored samples indefinitely unless the participant decide to withdraw from the project.

Participants may withdraw or cancel their permission for the use for their stored samples at any time. However, any samples and health information already obtained from their use will not be destroyed.

There will be no additional costs or charges to the participant for allowing the investigator to store and use their left over blood or saliva samples and there is no benefit to the participant for allowing the investigator to store their samples.

Participants will not be paid for donating their samples. The samples and information that the participants are donating will no longer belong to them. The research may lead to new medical knowledge, tests, treatments or products. These products could have some financial value. There are no plans to provide financial payment to either the participant or their relatives should this occur. ;


Study Design


Related Conditions & MeSH terms


NCT number NCT02724995
Study type Observational
Source University of Kentucky
Contact
Status Withdrawn
Phase N/A
Start date February 2016
Completion date December 2021

See also
  Status Clinical Trial Phase
Recruiting NCT05794217 - A Multi-Site Leukopak Repository Providing Annotated Biospecimens for Approved Investigator-Directed Biomedical Research Initiatives
Completed NCT03680365 - Your Voice; Impact of Duchenne Muscular Dystrophy (DMD) on the Lives of Families
Completed NCT03290469 - NICUSeq: A Trial to Evaluate the Clinical Utility of Human Whole Genome Sequencing (WGS) Compared to Standard of Care in Acute Care Neonates and Infants N/A
Not yet recruiting NCT05955794 - Vocal Pattern Assessment as a New Key to Identifying Rare Syndromes N/A
Recruiting NCT04429750 - Intact Cord Resuscitation in CDH N/A
Not yet recruiting NCT04152876 - Functional Genomics of Rare Genetic Diseases: Realization of Innovative Tools With High Diagnostic Power
Recruiting NCT03683966 - MigALastat Therapy Adherence Among FABRY Patients: A Prospective Multicentral Observational Study
Not yet recruiting NCT04319796 - European Registry on Rare Neurological Diseases
Completed NCT02736565 - Pbi-shRNAâ„¢ EWS/FLI1 Type 1 LPX in Subjects With Advanced Ewing's Sarcoma Phase 1
Completed NCT05070988 - Oral Health Related Quality of Life of Patients With Rare Diseases: a Qualitative Approach
Completed NCT03563677 - Dual Guidance Structure for Evaluation of Patients With Unclear Diagnosis in Centers for Rare Diseases N/A
Recruiting NCT05499091 - Functional Study to Indentify Genetic Etiology of Rare Diseases - ORIGIN N/A
Completed NCT03954652 - Whole Genome Trio Sequencing as a Standard Routine Test in Patients With Rare Diseases - "GENOME FIRST APPROACH" N/A
Recruiting NCT05703893 - Investigation of the Neurovegetative Pattern in Patients With Thoracic Aortic Aneurysms (TAA)
Enrolling by invitation NCT04703179 - Rare and Undiagnosed Disease Research Biorepository
Recruiting NCT04024774 - Diagnostic Research in Patients With Rare Diseases -Solving the Unsolved Rare Diseases
Recruiting NCT06343558 - Gait and Balance Impairment in Rare and Very Rare Neurological Diseases
Not yet recruiting NCT06412718 - Validation of Human Drugs Target of Repurposed Drugs and Novel Therapies
Enrolling by invitation NCT04654000 - Rheopheresis as Adjuvant Treatment of Calciphylaxis N/A
Recruiting NCT04651439 - Severe Bullous Drug Eruption and Filgrastim Phase 2/Phase 3